Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying. Aims: To assess ...

People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

"These drugs have the potential to change societies, not just individuals." — Michael Le Page, New Scientist, March 29, 2025 ...

Bariatric surgery; Obesity; Gastric bypass; Glucagon-like peptide 2; Glucagon-Like Peptide 1 RESUMO Racional: O papel de hormônios gastrointestinais sobre a homeostase glicêmica e a obtenção e ...

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming ...